Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis.

Akihiro MatsukawaPawel RajwaTatsushi KawadaKensuke BekkuEkaterina LaukhtinaJakob KlemmBenjamin PradereKeiichiro MoriPierre I KarakiewiczTakahiro KimuraPiotr ChlostaShahrokh F ShariatTakafumi Yanagisawa

Published in: International journal of clinical oncology (2024)

Triplet therapy improves OS in mHSPC patients compared to docetaxel-based doublet therapy, irrespective of disease volume. However, based on treatment ranking, triplet therapy should preferably be considered for patients with high-volume mHSPC while those with low-volume are likely to be adequately treated with ARSI + ADT.

Keyphrases

systematic review
prostate cancer
end stage renal disease
meta analyses
newly diagnosed
squamous cell carcinoma
small cell lung cancer
chronic kidney disease
prognostic factors
randomized controlled trial
radical prostatectomy
stem cells
energy transfer
patient reported outcomes
replacement therapy